e-learning
resources
ERJ
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme
Camille Taillé, Pascal Chanez, Gilles Devouassoux, Alain Didier, Christophe Pison, Gilles Garcia, Jeremy Charriot, Stéphane Bouée, Alina Gruber, Celine Pribil, Arnaud Bourdin, Marc Humbert
Source:
Eur Respir J, 55 (6) 1902345; 10.1183/13993003.02345-2019
Journal Issue:
June
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Camille Taillé, Pascal Chanez, Gilles Devouassoux, Alain Didier, Christophe Pison, Gilles Garcia, Jeremy Charriot, Stéphane Bouée, Alina Gruber, Celine Pribil, Arnaud Bourdin, Marc Humbert. Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. Eur Respir J, 55 (6) 1902345; 10.1183/13993003.02345-2019
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Anti-IL5 therapy could prevent lung function decline in severe eosinophilic asthma: data from the belgian severe asthma registry
Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough
Year: 2021
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Prevalence of oral corticosteroid use in the German severe asthma population
Source: ERJ Open Res, 5 (4) 00092-2019; 10.1183/23120541.00092-2019
Year: 2019
BTS Difficult Asthma Registry: Effect of omalizumab dosing table expansion on size of population of severe persistent allergic asthma patients potentially eligible for omalizumab therapy
Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma
Year: 2012
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study.
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Stopping
versus
continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study)
Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021
Year: 2022
Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Omalizumab reduces asthma exacerbations and oral corticosteroid use in patients with severe allergic asthma: a systematic review of observational studies
Source: International Congress 2019 – Clinical studies of asthma treatments
Year: 2019
Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study
Source: Annual Congress 2007 - Asthma subphenotypes
Year: 2007
Real-life effectiveness of anti-IL-5(-receptor) antibody treatment in patients with severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Efficacy of Omalizumab in adult and pediatric severe allergic asthma according to presence of multiple allergic comorbidities: evidence from the STELLAIR study.
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Mepolizumab for severe eosinophilic asthma: a comparison of efficacy in children, adolescents, and adults
Source: International Congress 2018 – New developments in paediatric asthma
Year: 2018
Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting
Source: International Congress 2017 – Asthma management
Year: 2017
The effects of early intervention with inhaled budesonide on lung function in mild persistent asthma: results from the START study
Source: Eur Respir J 2003; 22: Suppl. 45, 34s
Year: 2003
Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece.
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020
The use of omalizumab in the management of severe chronic paediatric asthma
Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma
Year: 2008
Pattern of asthma control and inhaled corticosteroid (ICS) use in an Australian asthma population
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept